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く〉原著 original papers 
1) Tsuchiya Y., Sawada S., Tsukada K. and Saiki I.: A new pseudo-peptide of Arg-Gly-Asp 
RGD) inhibits intrahepatic metastasis of orthotopically implanted murine hepatocellular carｭ
cinoma. InιJ, Oncol., 20: 319・324, 2002. 
Abstract: We have previously reported that the expression of matrix metalloproteinase-9 (MMP-9), membrane type-
1 matrix metalloproteinase (MTl-MMP) and betal integrins in murine hepatocellular carcinoma (HCC) was associｭ
ated with the occu町ence of intrahepatic metastasis, which is considered to be a m吋or modality in recu汀ence. Here 
we show that intravenous administration of synthetic RGD pseudo-peptide (FC-336) inhibited intrahepatic metastasis 
produced by orthotopic implantation of a fragment of murine HCC (CB0140C12) tumor as compared with control 
administration of vehicle (p<0.05), but did not affect the growth of the implanted tumor. To further analyze the antiｭ
metastatic effect of FC-336, we investigated the effects of FC-336 on tumor 、 growth, adhesion and invasion in vitro. 
FC-336 at non-cytotoxic concentration of less than 5 mg/ml effectively inhibited the adhesion and invasion of 
CB0140C12 cells (pく0.05). We also used zymography to examine the effect of FC-336 on the gelatinolysis of 
MMPs produced by CB0140C12 cels. FC-336 inhibited the degradation of the gelatin substrate by MMP-9 in a 
concentration-dependent manner. These results strongly suggest that intrahepatic metastasis of CB0140C12 tumors 
is partly due to the marked invasive and adhesive abilities of tumor cells mediated by expression of MMP-9 and 
integrin alpha3betal (VLA-3), integrin alpha5betal (VLA-5) on the tumor surface, respectively. 
2) Nagakawa 0., Murata J., Junicho A., Matsuda T., Fujiuchi Y., Fuse H. and Saiki I.: 
Vasoactive intestinal peptide (VIP) enhances the cell motility of androgen receptorｭ
transfected DU・145 prostate cancer cells (DU・145/AR). Cancer Lett., 176 : 93-99, 2002. 
Abstract: We established a clonal DU-145 prostate cancer cel line (DU-145/AR) stably transfected with androgen 
receptor (AR) cDNA and investigated the expression of type 1 vasoactive intestinal peptide (VIP) receptor (VIPlR) 
and type 2 VIP receptor (VIP2R) mRNA in these cells by reverse transcriptase-polymerase chain reaction analysis 
and the effect of VIP on the invasion and the haptotactic migration of these cels. DU-145/AR cells constitutively 
expressed both VIPlR and VIP2R mRNA, but the parent DU-145 cells did not. VIP increased the invasive capacity 
of DU-145/AR cels. VIP also enhanced the haptotactic migration of these cells to fibronectin. However, the growth 
of these tumor cells was not affected by VIP at any concentrations used in this study. These results indicate that VIP 
may play a role in the regulation of the invasion of prostate cancer. 
3 ) Sizemore N., Lerner N., Dombrowski N., Sakurai H. and Stark G.R.: Distinct'Roles of the IkB 
kinase a and b subunits in liberating nuclear factor kB (NF・kB) from IkB and in 
phosphorylating the p65 subunit of NF -kB. J. Biol. Chem., 277 : 3863・3869, 2002. 
Abstract: Phosphatidylinositol 3'-kinase (PI3K) and the serine/threonine kinase AKT have critical roles in 
phosphorylating and transactivating the p65 subunit of nuclear factor kappaB (NF-kappaB) in response to the proｭ
inflammatory cytokines interleukin-1 (IL-1) and tumor necrosis factor (TNF). Mouse embryo fibroblasts (MEFs) 
lacking either the alpha or beta subunit of IkappaB kinase (IKK) were deficient in NF-kappaB-dependent transcripｭ
tion following treatment with IL-1 or TNF. However, in contrast to IKKbeta-null MEFs, IKKalpha-null MEFs were 
not substantially defective in the cytokine-stimulated degradation of Ikappabetaalpha or in the nuclear translocation 
of NF-kappaB. The IKK complexes from IKKalpha-or IKKbeta-null MEFs were both deficient in PI3K-mediated 
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phosphorylation of the transactivation domain of the p65 subunit of NF-kappaB in response to IL-1 and TNF, and 
constitutively activated forms of PBK or AKT did not potentiate cytokine-stimulated activation of NF-kappaB in eiｭ
ther IKKalpha-or IKKbeta-null MEFs. Collectively, these data indicate that, in contrast to IKKbeta, which is reｭ
quired for both NF-kappaB liberation and p65 phosphorylation, IKKalpha is required solely for the cytokine-induced 
phosphorylation and activation of the p65 subunit of NF-kappaB that are mediated by the PBK/AKT pathway. 
4) Mizukami J., Takaesu G., Akatsuka H., Sakurai H. Ninomiya-Tsuji J., Matsumoto K.and 
Sakurai N.: Receptor activator of NF-kB ligand (RANKL) activates TAKI mitogen・activated
protein kinase kinase kinase through a signaling complex containing RANK, T AB2, and 
TRAF6. Mol. Cell. Biol., 22: 992・1000, 2002. 
Abstract: The receptor activator of NF-kappaB (RANK) and its ligand RANKL are key molecules for differentiaｭ
tion and activation of osteoclasts. RANKL stimulates transcription factors AP-1 through mitogen-activated protein 
kinase (MAPK) activation, and NF-kappaB through IkappaB kinase (IKK) activation. Tumor necrosis factor recepｭ
tor-associated factor 6 (TRAF6) is essential for activation of these kinases. In the interleukin-I signaling pathway, 
TAKI MAPK kinase kinase (MAPKKK) mediates MAPK and IKK activation via interaction with TRAF6, and 
TAB2 acts as an adapter linking TAKI and TRAF6. Here, we demonstrate that TAKI and TAB2 participate in the 
RANK signaling pathway. Dominant negative forms of TAKI and TAB2 inhibit NF-kappaB activation induced by 
overexpression of RANK. In 293 cells stably transfected with full-length RANK, RANKL stimulation facilitates the 
formation of a complex containing RANK, TRAF6, TAB2, and TAKI, leading to the activation of TAKI. 
Furthermore, in murine monocyte RAW 264.7 cels, dominant negative forms of TAKI and TAB2 inhibit NFｭ
kappaB activation induced by RANKL and endogenous TAKI is activated in response to RANKL stimulation. 
These results suggest that the formation of the TRAF6-TAB2-TAK1 complex is involved in the RANK signaling 
pathway and may regulate the development and function of osteoclasts. 
5) Sawada S., Murakami K., Yamaura T., Mitani N., Tsukada K. and Saiki I.: Therepeutic and 
analysis model of intrahepatic metastasis reflects clinical behavior of hepatocellular carciｭ
noma. Jpn. J. Cancer Res., 93 : 190・197, 2002. 
Abstract: This study was designed to establish an intrahepatic metastasis model to investigate the biology and therｭ
apy of hepatocellular carcinoma (HCC) in mice. A fragment of mouse HCC tumor CBOI40Cl2 was orthotopically 
implanted into the mouse liver. The number of intrahepatic metastatic colonies and the volume of the implanted 
tumor increased in a time-dependent manner. At 28 days after fragment implantation, al mice showed intrahepatic 
metastasis. Intravenous administrations of cisplatin and doxorubicin at 7 and 21 days after the implantation signifiｭ
cantly suppressed the growth of the primary tumor nodule, but tended to inhibit intrahepatic metastasis. However, 
a marked decrease of body weight was observed during the experiment. On the other hand, an inhibitor of matrix 
metalloproteinases (MMPs ),ON0-48 I 7,decreased the gelatinase activity of MMP-9 secreted by CBO l 40C 12 cels, 
and significantly reduced the number of colonies of intrahepatic metastasis when administered orally. Our es tabｭ
lished model, which is focused on intrahepatic metastasis, is suitable for evaluating the therapeutic effect of HCC 
and for analyzing intrahepatic metastasis, because this model reflects the clinical features of HCC and al the steps 
of tumor metastasis. 
6) Tatsumi T., Terasawa M., Tega E., Hayakawa Y., Terasawa K. and Saiki I.: Immunopharmaｭ
cological properties of Oren-gedoku・to (a Kampo medicine, Huang-Lian-Jie-Du-Tang) on 
contact hypersensitivity reaction in mice. J. Trad. Med., 19: 21・27, 2002. 
Abstract: We investigated the effects of Oren-gedoku-to (Huang-Lian-Jie-Du-Tang), a Kampo medicine, on DNFBｭ
induced contact hypersensitivity (CHS) response in mice in order to further clarify the immunopharmacological 
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properties of this formulation. 1) Administration of Oren-gedoku-to decreased the magnitude of ear swelling in the 
CHS response and shortened the affected period. The inhibitory effect on ear swelling was observed even . when 
Oren-gedoku-to was given orally with different timing schedules. 2) The expressions of mRNAs for CD8, IFN-r 
and TNF－ αin the ear of Oren-gedoku-to-treated mice were markedly decreased 24 h after the challenge. 3) The 
number of skin-draining regional lymph node cells (LNC) was decreased without affecting the ratio of CD8+/CD4+ 
T cels. Oren-gedoku-to resulted in a marked impairment of the hapten-specific development of lymphocytes. These 
results suggest that the suppressive effect of Oren-gedoku-to on ear swelling was p訂tly caused by the suppression 
of lymphocyte proliferation. 
7) Muraishi Y., Mitani N., Fuse H. and Saiki I.: Effect of a Matrix metalloproteinase inhibitor 
(ONO・4817) on lung metastasis of murine renal cell carcinoma. Anticancer Res., 21 : 3845・
3852, 2002. 
Abstract: We examined the anti-metastatic effect of a newly developed inhibitor of synthetic matrix 
metalloproteinase (MMP), ON0-4817, on experimental pulmonary metastasis of murine renal cell carcinoma 
(Renca) cells and on tumor cel invasion, through reconstituted basement membrane (Matrigel) in vitro using the 
same cels. Oral administration of ON0-4817 (50-200 mg/kg/day) to Renca-bearing mice resulted in a doseｭ
dependent inhibition of lung metastasis without a loss of body weight. ON0-4817 at the high dose of 200 mg/kg 
showed a tendency to prolong the survival of the mice. We also found that oral administration of ON0-4817 signifiｭ
cantly inhibited the angiogenic response (number of vessels oriented towards the tumor mass) and the growth of tuｭ
mors inoculated i.d. in syngeneic mice. In addition, ONO・4817, at non-cytotoxic concentrations of less than 10 
microM, caused a marked inhibition of the invasion of Renca cells as comp訂ed to the vehicle control. Gelatin 
zymography revealed that ON0-4817 inhibited the enzymatic activity of MMP-2 produced by Renca cells in a conｭ
centration-dependent manner. In conclusion, ON0-4817 effectively inhibited lung metastasis of Renca cells through 
its anti-invasive and anti-angiogenic properties. These results suggest that use of the MMP inhibitor (MMPI) ONO-
481 7 may provide a therapeutic basis for preventing lung recu汀ence and metastasis of renal cel carcinoma. 
8) Ueda J., Tezuka Y., Banskota A.J., Tran G.L., Tran Q.K., Harimaya Y., Saiki I. and Kadota 
S.: Antiproliferative activity of vietnamese medicinal plants. Biol. Pharm. Bull., 25 : 753-760, 
2002. 
9) Sasamura T., Nakamura S., Iida Y., Fujii H., Murata J., Saiki I. Nojima H. and Kuraishi Y.: 
Morphine analgesia suppresses tumor growth and metastasis in a mouse model of cancer pain 
produced by orthotopic tumor inoculation. Eur. J. Pharmacol, 441: 185・191, 2002. 
10) Tran Q.L., Adnyana I.K., Tezuka Y .,Harimaya Y .,Saiki I., Kurashige Y .,TranQ.K. and 
Kadota S.: Hepatoprotective effect of majonoside R2, the major saponin from Vietnamese 
ginseng (Panax vietnamensis). Planta Med., 68: 402-406, 2002. 
11) Hasegawa H. Suzulki R., Nagaoka T., Tezuka Y., Kadota S. and Saiki I.: Prevention of growth 
and metastasis of murine melanoma through enhanced natural-killer cytotoxicity by fatty 
acid-conjugate of protopanaxatriol. Biol. Pharm. Bull., 25 : 861・866, 2002. 
Abstract: Ginsenosides, the glycosides of Panax ginseng, are metabolized (deglycosylated) by intestinal bacteria 
after oral administration. 20(S)”Protopanaxatriol (M4) is the main bacterial metabolite of protopanaxatriol-type 
ginsenosides and mediates their antitumor effects. To clarify the mechanism of the M4四mediated antitumor effect, 
the antitumor activity and metabolism of M4 was examined, using the C57BL/6 mice implanted with B16-BL6 
melanoma. The chronic oral administration of M4 inhibited the growth of B 16-BL6 melanoma at the implanted site. 
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Analyses using TLC, HPLC, MS and NMR suggest that orally administered M4 was absorbed from the small intes事
tine into the mesenteric lymphatics followed by the rapid esterification of M4 with fatty acids and its accumulation 
in the tissues including the liver and lung. The administration of M4 prior to the intravenous injection of B 16-BL6 
cells abrogated the enhanced lung metastasis in the mice pretreated with 2・chloroadenosine more effectively than in 
those pretreated with anti-asialo GMl. The esterified M4 (EM4) did not directly affect tumor growth in vitro, 
whereas it stimulated splenic NK cells to become cytotoxic to tumor cels. These results indicate that the antitumor 
activity of M4 isbased on the NK cell-mediated tumor lysis enhanced by EM4. 
12) Nakamura E.S., Kurosaki F., Arisawa 島'I., Mukainada T .,Takayasu J .,Okuda M., Nishino H. 
Pastore F. Jr.: Cancer chemopreventive e町ects of a Brazilian folk medicine, Juca, on in vivo 
two-stage skin carcinogenesis. J. Ethnopharmacol., 81 : 135-137, 2002. 
Abstract: Gallic acid (1) and methyl gallate (2) were isolated from Juca, a Brazilian folk medicine, fruits of 
Caesalpinia fe町ea MART (Leguminosae), decreased significantly the average number of papillomas per mouse in 
the experiment of the promoting effects of 12-0-tetra岨 decanoylphorbol-13-acetate (TPA) on skin tumor formation 
in mice initiated with 7,12-dimethylbenz[a]anthracene (DMBA). 
13) Matsuo M., Tani T. and Saiki I.: Organ selectivity of Juzen-taiho・to and Ninjin-yoei-to in the 
expression of anti-metastatic efficacy. J. Trad. Med., 19: 93-97, 2002. 
Abstract: We investigated the inhibitory effect of oral administration of Juzen-taiho-to and Ninjin-yoei-to on the 
liver metastasis caused by intraportal vein injection of colon 26・L5 cells and lung metastasis by intravenous injection 
of same tumor cels. Juzen-taiho-to significantly inhibited liver metastasis but not lung metastasis. In contrast, 
Ninjin-yoei-to was effective at inhibiting lung metastasis but not liver metastasis. In the experimental liver and lung 
metastasis model using same tumor in syngeneic mice system, oral administration of both formulations showed difｭ
ferential pattern with organ selectivity for the expression of anti-metastatic effects. These results suggest that the diι 
ferent expression of the anti-metastatic effects of both Kampo medicines on tumor metastasis are partly based on the 
medicinal guides according to the theory of Jing and Lun (lnkei-hoshi) formed in 13th century. 
14) Hasegawa H. and Saiki I.: Psychosocial stress augmen臼 tumor development throughβ ． 
adrenergic activation in mice. Jpn. J. Cancer Res., 93 : 729・735, 2002. 
Abstract: Housng conditions affect behavioral and biological responses of animals. We investigated the effect of 
same-sex-grouped (G), crowded (GC) and isolated (I) conditions on the growth of B16 melanoma or Meth A 
fibrosarcoma implanted in the footpad of syngeneic male C57BL I 6 or BALB I c mice. Differential housing altered 
host resistance to tumor growth. The host responses to stress were reflected in thymic atrophy, which was lowest in 
the G mice, highest in the GC mice and intermediate in the I mice. The GC condition was a more stressful social 
environment than the I condition in both male C57BL I 6 and BALB I c mice. Reflecting the extent of psychosocial 
stress, tumor growth was augmented in the order of GC, I and G condition, and a negative mass correlation between 
tumor and thymus was observed, thus clearly indicating that the host resistance to tumors was attenuated by 
psychosocial stres. Furthermore, the stress-enhanced tumor growth and thymus atrophy were completely abrogated 
by the oral administration of the non-selective beta-adrenergic antagonist, propranolol. On the contrary, the chronic 
administration of corticosterone significantly induced the atrophy of thymus and spleen without affecting tumor 
growth. These results suggest an interrelationship among psychosocial stress, tumor growth and beta-adrenergic acｭ
tivation. 
15) Nagaoka T., Banskota A.H., Tezuka Y., Saiki I. and Kadota S.: Selective antiproliferative ac・
tivity of caffeic acid phenethyl ester analogues on highly liver-metastatic murine colon 26・LS
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carcinoma cell line. Bioorg. Med. Chem., 10 : 3351・3359, 2002. 
16) Nakamura E.S., Kurosaki F., Arisawa M., Mukainada T., Okuda M., Takayasu J., Nishino H. 
Pastore F. Jr.: Cancer chemopreventive effec飴 of constituents of Caesalpinia f errea and reｭ
lated compounds. Cancer Let., 177 : 119・124, 2002. 
Abstract: The anti-tumor promoting effects of fruits of Caesalpinia feπea MART. (Leguminosae) were tested by the 
in vitro Epstein-Baπvirus early antigen (EBV-EA) activation assay, and its active constituents were identified as 
gallic acid (1) and methyl gallate (2). A total of 49 related compounds of 1 and 2 were analysed for the effects by 
this assay, and the structure activity relationships have been proposed. Three acetophenone derivatives, 2,6-
dihydroxyacetophenone ( 48), 2,3,4-trihydroxyacetophenone (50) and 2,4,6-trihydroxy-acetophenone (51) were 
found to show potent inhibitory 
17) Hayakawa Y., Takeda K., Yagita H., Smyth M.J., Kae L.V., Okumura K. and Saiki I.: IFN-
7 ・mediated inhibition of tumor angiogenesis by the natural killer T cell ligand， α －galacto・
sylceramide. Blood, 100 : 1728-1733, 2002. 
Abstract : Alpha-galactosylceramide (alpha-GalCer), which is a specific ligand for CDld-restricted vaiiableｭ
alpha14 chain (V(alpha)14) natural killer T (NKT) cels, exerts a potent antitumor effect. We recently demonstrated 
that interferon-gamma (IFN-gamma) secreted by both NKT cells and NK cells plays a critical role in mediating the 
antimetastatic effect of alpha-GalCer; however, the IFN-gamma-dependent antitumor mechanisms remain poorly deｭ
fined. In the present study, we demonstrate IFN-gamma-dependent inhibition of tumor angiogenesis by alphaｭ
GalCer. In alpha-GalCer-treated mice, subcutaneous tumor growth and tumor-induced angiogenesis were inhibited 
in an IFN-gamma-dependent manner. The alpha-GalCer-activated splenic or hepatic mononuclear cells inhibited 
murine endothelial cel proliferation in vitro, and this inhibitory effect was mediated mostly by IFN-gamma pro” 
duced by NKT cells and NK cels. NK cel depletion resulted in significant but partial inhibition of tumor growth 
and angiogenesis in vivo. These results suggest that the IFN-gamma-mediated inhibition of tumor angiogenesis is 
critically involved in the effector mechanisms of antitumor effects evoked by alpha-GalCer. 
18) Harimaya Y., Koizumi K., Andoh T円 Nojima H., Kuraishi Y. and Saiki I.: Potential ability of 
morphine to inhibit the adhesion, invasion and metastasis of metastatic colon 26・LS carciｭ
noma cells. Cancer Lett., 187: 121-127, 2002. 
Abstract: Morphine is frequently used for cancer patient’s terminal medical c訂e to relieve cancer pain. In the preｭ
sent study, we examined the inhibitory effect of morphine on experimental lung metastasis and invasion of colon 26-
L5 cels. Mo叩hine was found to significantly reduce the number of tumor colonies and the weight of the tumorｭ
containing lung. Morphine inhibited the adhesion and migration of colon 26-L5 cells to extracellular matrix 
components and invasion into reconstituted basement membrane Matrigel, without affecting the cel proliferation in 
vitro. Notably, naloxone, an antagonist of morphine, abrogated morphine-induced inhibition of tumor cel adhesion, 
but did not affect the inhibitory effect on the production of matrix metalloproteinases (MMPs) from tumor cels. 
These results suggest that mo中hine inhibited the adhesive and invasive properties of tumor cells by different inhibiｭ
tory mechanisms that involved the mediation of an opioid receptor. 
19) Sakurai H., Nishi A., Sato N .,Mizukami J.，民1iyoshi H. and Sugita T.: TAKl・TABl fusion 
protein: a novel constitutively active mitogen-acbvated protein kmase kinase kinase that 
stimulates AP-1 and NF・kB signaling pathway. Biochem. Biophys. Res. Commun. 297: 1277・
1281, 2002. 
Abstract: TAKI mitogen-activated protein kinase kinase kinase (MAP3K) is activated by its specific activator, 
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TAKI-binding protein 1 (TABl). A constitutively active TAKl mutant has not yet been generated due to the indisｭ
pensable requirement of TABl for 'tAKl kinase activity. In this study, we generated a novel constitutively active 
TAKl by fusing its kinase domain to the minimal TAKI-activation domain of TAB 1.Co-immunoprecipitation assay 
demonstrated that these domains.interacted intra-molecularly. The TAKI・TAB1 fusion protein showed a significant 
MAP3 activity in vitro and activated c-Jun N-terminal kinase/p38 MAPKs and IkappaB kinase in vivo, which was 
followed by increased production of interleukin-6. These results indicate that the fusion protein is useful for characｭ
terizing the physiological roles of the TAKl-TABl complex. 
20) Ogasawara M., Matsunaga T., Takahashi S., Saiki I. and Suzuki H.: Anti-invasive and 
metastatic activities of evodiamine. Biol. Pharm. Bull., 25: 1491-1493, 2002. 
Abstract: We have recently reported that evodiamine can suppress in vitro invasion and lung metastasis by colon 
26-L5 carcinoma cels. To extend our study, we examine here the anti-invasive and metastatic effects of evodiamine 
on Lewis lung carcinoma (LLC) and B16-F10 melanoma in addition to colon 26-L5 carcinoma. Critical structures 
of evodiamine for the activities were also evaluated by comparison with compounds possessing structures similar to 
that of evodiamine. Evodiamine concentration-dependently inhibited the invasion of B 16-FlO, LLC and colon 26-L5 
cells with IC(50) values of 2.4 micro M, 4.8 micro M and 3.7 micro M, respectively. Pre-treatment of colon 26-L5 
cells with evodiamine before inoculation into mice caused significant suppression of the liver metastasis as well as 
the lung metastasis. Lung metastasis by LLC is also inhibited significantly by pre-exposure to evodiamine. When the 
anti-migratory activity of evodiamine was comp訂ed with that of evodiamine-like compounds, rutaecarpine lacking 
a methyl group at N-14 and a hydrogen at C-13 b exhibited much less effect than evodiamine. In addition, reserpine, 
having beta-configurated hydrogen at C-13 b, inhibited tumor cell migration more potently than yohimbine, having 
alpha-configurated hydrogen at the same position. These results suggest that evodiamine may be useful as a leading 
compound for agents in tumor metastasis therapy. Also, the presence of a methyl group at N-14 and the configuraｭ
tion of hydrogen at C-13 b may be responsible for the inhibitory activities of evodiamine. 
21) Siripong P., Nakamura E.S., Kanokmedhakul K., Ruchirawat S. and Saiki I.: Anti-invasive 
e釘ec旬。fcurucuminoid compounds from Curcuma aromatica Salish. on murine colon 26・LS
carcinoma cells. J. Trad, Med., 19: 209-215, 2002. 
Abstract: Bioassay-directed fractionation of the active chloroform extract from the rhizomes of Curcuma aromatica 
Salisb. (Zingiberaceae) led to the isolation of four main curcuminoid constituents: curcumin (CA司 1), demethoxycu・
rcumin (CA・2），デーmethoxycurcumin (CA-3) and bisdemethoxycurcumin (CA-4). This is the first report to describe 
the isolation of CA-3 from C. aromatica. The chemical structures of these compounds were determined on the basis 
of spectral analysis and their inhibitory effects on the proliferation, invasion and migration of murine colon 26-L5 
adenocarcinoma cells were evaluated in vitro. Curcumin and its analogues (CA-2, 3 and 4), at the non-cytotoxic conｭ
centration of 10 mM, inhibited the invasive ability of colon 26-L5 cells to the ranges of 22.8, 28.9, 10.3 and 62.0%, 
respectively. A similar effect of these constituents on the migration of colon 26-L5 cells was also observed. Among 
these curcuminoids, CA-4 showed the strongest activities, inhibiting both tumor cell invasion and migration in a conｭ
centration-dependent manner. 
く〉総説 Review Paper 
1 ）済木育夫：特集団BM にもとづくアレルギー疾患の漢方治療」，講座 アレルギー性皮膚疾患に用いら
れる漢方方剤，アレルギー・免疫， 9: 790-799, 2002. 
2 ）済木育夫：連載「現代西洋医学からみた東洋医学」，漢方薬の抗腫蕩効果とその作用機序 －補剤を用
いた癌転移の抑制－，医学のあゆみ， 202 : 205-209, 2002. 
3 ）済木育夫：スペシャルインタビ、ュー「スピルリナJ，体と栄養のメカニズム，元気生活， 90 : 34-41, 2002. 
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4 ）済木育夫： 4. 補剤現代医学の立場から，第 1 4 回伝統医学臨床セミナー「虚弱者に頻用される処方」，
日本東洋医学雑誌， 53: 297-309, 2002. 
5 ）済木育夫：特別講演「漢方方剤のアレルギー性疾患治療への応、用－基礎からの提言－」，日本小児東洋
医学会誌， 18 : 21-26, 2002. 
6 ）済木育夫：特集癌免疫治療と漢方の位置づけ， BRMとしての十全大補湯は IFN－ αA/Dのマウス腎
細胞癌に対する肺転移抑制効果を著明に増強する， T-webs, 6 : 10-13, 2002. 
く〉学会報告 Scientific presentation ( ＊：特別講演，シンポジウム，ワークショップ等）
* 1) 済木育夫： シンポジウム「アレルギー疾患における漢方薬の特性と有用性」，アレルギー性疾患に用い
られる漢方方剤の基礎的研究，第21回漢方免疫アレルギー研究会学術集会， 2002, 01. 26，東京．
2 ）済木育夫：アレルギー疾患に用いられる漢方薬の基礎的研究，皮膚科漢方入門セミナー， 2002, 03. 17. 
富山．
*3 ）済木育夫：ミニシンポジウム「新しいコンセプ卜による天然薬物の薬効解析」，漢方薬の薬効ならびに
証の解明に向けて，日本薬学会第121年会総会， 2002, 03. 26-28，千葉．
事 4 ）済木育夫：特別講演：肺癌の縦隔リンパ節転移モデルの作製と転移抑制の試み，第 6 回富山肺癌化学療
法セミナー， 2002, 04. 17. 富山．
* 5 ) Saiki I.: A Kampo medicine Juzen-taiho-to: Prevention of malignant progression and metastasis of tumor 
cels and the mechanism of action. 2002 International Symposium of Traditional Korean Medicine -What is 
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一木克之： Mediastinal lymph node metastasis model by orthotopic intrapulmonary implantation of Lewis lung 
carcinoma cells in mice. 
医学博士（富山医科薬科大学）
村石康博： Establishment of the model of intrahepatic metastasis by orthotopic implantation of a fragment of 
murine hepatocellular carcinoma and analysis of molecules related to intrahepatic metastasis 
医学博士（富山医科薬科大学）
※横山悟： 修士課程修了後，東北大学大学院医学研究科博士課程に進学，
播磨谷優子：修士課程修了後，秋田大学附属病院薬剤部，薬剤師
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